Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the followup protocol

• Published in: The Journal of urology Vol. 161; no. 2; p. 472
• Main Authors: Sharir, S, Jewett, M A, Sturgeon, J F, Moore, M, Warde, P R, Catton, C N, Gospodarowicz, M K
• Format: Journal Article
• Language: English
• Published: United States 01.02.1999
• Subjects: Adolescent; Adult; Clinical Protocols; Disease Progression; Follow-Up Studies; Humans; Male; Neoplasm Staging; Prospective Studies; Retrospective Studies; Testicular Neoplasms - mortality; Testicular Neoplasms - pathology; Testicular Neoplasms - therapy
• ISSN: 0022-5347
• DOI: 10.1016/S0022-5347(01)61926-8

To optimize followup in patients with stage I nonseminomatous testis cancer on surveillance we evaluated the contribution of each followup modality to the detection of progression as well as morbidity and mortality outcomes. After orchiectomy 170 patients with clinical stage I nonseminoma were prospectively placed on a surveillance protocol. History, physical examination, serum tumor markers, abdominal and pelvic computerized tomography (CT), and chest x-ray were used for followup. The number of failures, methods and timing of progression detection, treatments required, mortality rate and subsequent contralateral primary tumors were recorded. The 170 surveillance patients were followed a median of 6.3 years. Within 2 years (median 6.9 months) postoperatively 48 patients (28.2%) had disease progression. History, physical examination, markers, CT and chest radiography provided the initial evidence of progression in 18 (37.5%), 34 (70.8%), 34 (70.8%), and 4 (8.3%) patients, respectively. Each modality was the only indicator of failure in 2 (4.2%), 4 (8.3%), 10 (20.8%) and 0 cases, respectively. Of the 170 patients 122 (71.8%) required no additional treatment beyond orchiectomy, 26 (15.3%) received 1 and 22 (12.9%) underwent more than 1 therapeutic modality. Only 1 patient (0.6%) died of disease. Contralateral tumors developed in 5 cases (2.9%) therapeutic a mean of 8.1 years after orchiectomy. In stage I nonseminoma patients, surveillance history, physical examination, tumor markers and abdominopelvic CT are necessary components of the followup protocol. Removal of routine chest x-ray from the protocol would not have changed progression detection. The initial surveillance visit must occur by 2 months postoperatively. Patients should be followed beyond 5 years and likely for life in addition to regular patient self-examination.